WhaleCreep

Avidity Partners Management LP 13F holdings, Q4 2019

Hedge fundSEC filingsCompare with another fundHoldings as of 2019-12-31, filed 2020-06-17

Avidity Partners Management LP disclosed 33 US equity positions worth $158.7m in its Q4 2019 13F filing. Its largest position is BAX at 8.7% of the reported book, followed by HCA and VRTX.

$159m
Reported equity book
Sum of the long US equity positions in the filing, at the values filed. Options are excluded.
33
Positions
Distinct securities in the equity book with a reported value above zero. Options are excluded.
8.7%
Largest position
The largest single position as a share of the reported equity book.
52.1%
Top 10 weight
The ten largest positions together, as a share of the reported equity book.
24
Effective positions
1 / HHI of portfolio weights: the number of equal-weight positions the book behaves like.
27
Quarters on file since Q4 2019
Quarters for which this manager's 13F holdings are on record.

Holdings

33 rows
BAX BAXTER INTL INCHealthcare8.7%$13.8m165,000–
HCA HCA HEALTHCARE INCHealthcare5.8%$9.3m62,700–
VRTX VERTEX PHARMACEUTICALS INCHealthcare5.5%$8.8m40,000–
ABBV ABBVIE INCHealthcare5.2%$8.3m94,000–
MRTXEUR MIRATI THERAPEUTICS INC–5.2%$8.2m64,000–
ZBH ZIMMER BIOMET HOLDINGS INCHealthcare5.1%$8.2m54,500–
ESPREUR ESPERION THERAPEUTICS INC NE–4.9%$7.8m130,400–
EW EDWARDS LIFESCIENCES CORPHealthcare4.0%$6.3m27,000–
CI THE CIGNA GROUPHealthcare3.9%$6.1m30,000–
ASND ASCENDIS PHARMA A/SHealthcare3.7%$5.9m42,100–
AXNX* AXONICS INC–3.6%$5.8m208,000–
HORIZON THERAPEUTICS PUB L no ticker–3.4%$5.4m150,000–
NXTC NEXTCURE INC–3.3%$5.2m93,000–
CTLTEUR CATALENT INC–3.3%$5.2m92,000–
AUPH AURINIA PHARMACEUTICALS INCHealthcare3.0%$4.7m232,000–
DVAX DYNAVAX TECHNOLOGIES CORP–2.8%$4.5m780,000–
ABEO ABEONA THERAPEUTICS INC–2.7%$4.3m1.32m–
DXCM DEXCOM INCHealthcare2.6%$4.2m19,000–
MNTA MOMENTA PHARMACEUTICALS INC–2.5%$3.9m200,000–
UNIQURE NV no ticker–2.5%$3.9m55,000–
CHRS COHERUS ONCOLOGY INCHealthcare2.4%$3.9m214,500–
KDMN KADMON HLDGS INC–2.4%$3.8m830,000–
COLL COLLEGIUM PHARMACEUTICAL INCHealthcare2.3%$3.7m180,000–
NBIX NEUROCRINE BIOSCIENCES INCHealthcare2.2%$3.5m33,000–
IMMU IMMUNOMEDICS INC–1.9%$3.0m140,000–
EXK EXACT SCIENCES CORPBasic Materials1.8%$2.9m31,000–
NEOLEUKIN THERAPEUTICS INC no ticker–1.6%$2.6m210,000–
ACAD ACADIA PHARMACEUTICALS INCHealthcare1.5%$2.3m54,000–
MDGL MADRIGAL PHARMACEUTICALS INCHealthcare0.9%$1.4m15,000–
RCKT ROCKET PHARMACEUTICALS INCHealthcare0.4%$683k30,000–
SNSSEUR SUNESIS PHARMACEUTICALS INC–0.3%$473k1.40m–
VSAREUR ARAVIVE INC–0.3%$410k30,000–
RLMD RELMADA THERAPEUTICS INCHealthcare0.2%$390k10,000–

Sector mix

  • Healthcare57.5%
  • Unclassified40.7%
  • Basic Materials1.8%

Book over time

Every quarter on file (27)
QuarterPositionsEquity book
Q2 202645$624m
Q1 202645$494m
Q4 202539$347m
Q3 202543$439m
Q2 202555$499m
Q1 202563$485m
Q4 202461$1.0bn
Q3 202481$2.0bn
Q2 202485$2.4bn
Q1 202487$2.8bn
Q4 202372$2.6bn
Q3 202383$2.5bn
Q2 202393$2.9bn
Q1 202383$3.0bn
Q4 202284$4.3bn
Q3 202296$4.6bn
Q2 202282$4.4bn
Q1 202291$4.5bn
Q4 202197$4.7bn
Q3 2021103$3.9bn
Q2 2021112$3.7bn
Q1 202193$3.6bn
Q4 202094$3.0bn
Q3 202066$1.9bn
Q2 202057$1.6bn
Q1 202049$698m
Q4 201933$159m

Where Avidity Partners Management LP was early

46 rows
BTAI BIOXCEL THERAPEUTICS INCQ1 20202 of 560.7%1.3%4Exited by Q1 2021+3.4%
ALEC ALECTOR INCQ1 20205 of 872.5%2.5%2Exited by Q3 2020+1.3%
VSTM VERASTEM INCQ1 20205 of 1001.1%1.1%2Exited by Q3 2020−35%
AXSM AXSOME THERAPEUTICS INCQ1 20208 of 1411.7%2.1%17Exited by Q3 2025+77%
IDYA IDEAYA BIOSCIENCES INCQ2 20201 of 1081.2%2.9%19Exited by Q2 2025+15%
ZNTL ZENTALIS PHARMACEUTICALS INCQ2 20203 of 872.1%4.8%14Exited by Q4 2023−58%
VIR VIR BIOTECHNOLOGY INCQ2 20204 of 1141.6%1.7%11Held at last filing, Q2 2026−75%
LEGN LEGEND BIOTECH CORPQ2 20205 of 1210.3%2.6%14Held at last filing, Q2 2026−32%
NTLA INTELLIA THERAPEUTICS INCQ2 20206 of 1290.6%1.7%16Held at last filing, Q2 2026−20%
SNDX SYNDAX PHARMACEUTICALS INCQ2 20206 of 1271.5%3.5%21Exited by Q3 2025−37%
ARVN ARVINAS INCQ2 20208 of 1212.3%5.1%22Exited by Q4 2025−75%
AVTR AVANTOR INCQ2 20209 of 1841.8%6.2%17Exited by Q2 2025−4.7%
NBP I MABQ3 20202 of 663.4%3.4%5Exited by Q4 2021+54%
NTRA NATERA INCQ3 202010 of 1672.0%6.8%23Exited by Q2 2026+177%
MRVI MARAVAI LIFESCIENCES HLDGS IQ4 20201 of 1163.2%3.3%3Exited by Q3 2021+49%
ATEC ALPHATEC HLDGS INCQ4 20203 of 1020.9%1.1%10Exited by Q4 2023−11%
ORGO ORGANOGENESIS HLDGS INCQ4 20203 of 671.4%1.4%2Exited by Q2 2021+142%
SHC SOTERA HEALTH COQ4 20203 of 1320.6%1.6%5Exited by Q1 2022−14%
STTK SHATTUCK LABS INCQ4 20203 of 651.7%1.7%5Exited by Q1 2022−84%
SGRY SURGERY PARTNERS INCQ4 20205 of 1320.5%3.8%11Exited by Q1 2025−27%
IMCR IMMUNOCORE HLDGS PLCQ1 20212 of 970.7%2.1%15Exited by Q4 2024−27%
NUVB NUVATION BIO INCQ1 20213 of 972.2%2.2%6Exited by Q3 2022−69%
ACET ADICET BIO INCQ1 20217 of 720.8%1.4%5Exited by Q2 2022+53%
CGEM CULLINAN THERAPEUTICS INCQ1 20219 of 920.8%1.2%3Exited by Q4 2024−60%
BBIO BRIDGEBIO PHARMA INCQ1 202113 of 1741.4%1.4%6Held at last filing, Q2 2026+21%
CMPS COMPASS PATHWAYS PLCQ2 20214 of 1071.0%1.0%2Exited by Q4 2021−22%
DOCS DOXIMITY INCQ2 20218 of 1330.2%1.5%3Exited by Q3 2025+5.4%
STVN STEVANATO GROUP S P AQ3 20212 of 621.6%1.6%2Exited by Q1 2022−11%
CRBU CARIBOU BIOSCIENCES INCQ3 20214 of 731.5%1.5%11Exited by Q2 2024−78%
ALT ALTIMMUNE INCQ3 20218 of 1040.6%1.5%10Exited by Q3 2025−66%
KYMR KYMERA THERAPEUTICS INCQ3 20219 of 980.8%2.0%4Exited by Q1 2025−32%
RARE ULTRAGENYX PHARMACEUTICAL INQ3 20219 of 1511.0%3.2%16Exited by Q3 2025−60%
RVMD REVOLUTION MEDICINES INCQ2 20228 of 1640.6%1.9%14Exited by Q2 2026+399%
PLRX PLIANT THERAPEUTICS INCQ3 202210 of 1030.9%2.4%4Exited by Q3 2023−13%
TMDX TRANSMEDICS GROUP INCQ3 202210 of 1080.3%1.2%3Exited by Q1 2025+49%
PCVX VAXCYTE INCQ3 202213 of 1210.3%1.8%9Exited by Q2 2025+57%
BHVN BIOHAVEN LTDQ4 20229 of 1260.5%1.9%10Exited by Q2 2025+73%
ICLR ICON PLCQ4 202215 of 1611.0%1.7%4Exited by Q2 2026−43%
GPCR STRUCTURE THERAPEUTICS INCQ2 20239 of 1140.06%1.8%8Held at last filing, Q2 2026+29%
MLTX MOONLAKE IMMUNOTHERAPEUTICSQ2 202311 of 1210.7%1.8%4Exited by Q2 2026−63%
NMRA NEUMORA THERAPEUTICS INC.Q3 20233 of 751.0%1.3%5Exited by Q4 2024−6.4%
DNTH DIANTHUS THERAPEUTICS INCQ3 20235 of 970.7%35.8%12Held at last filing, Q2 2026+613%
CGON CG ONCOLOGY INCQ1 20242 of 882.3%17.7%10Held at last filing, Q2 2026+62%
JANX JANUX THERAPEUTICS INCQ1 20249 of 1090.5%4.0%5Exited by Q2 2025−28%
ORKA ORUKA THERAPEUTICS INCQ3 20247 of 831.0%11.6%8Held at last filing, Q2 2026+288%
JBIO JADE BIOSCIENCES INCQ2 20252 of 522.3%6.2%5Held at last filing, Q2 2026+122%

Concentration and tenure

6.2%
Median largest position, all quarters
The largest single position as a share of the reported equity book.
39.7%
Median top 10 weight, all quarters
The ten largest positions together, as a share of the reported equity book.
Concentrated
Style, by median largest position
2
Median completed holding, quarters